(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 9 June 2005 (09.06.2005)

PCT

(10) International Publication Number WO 2005/051890 A1

- (51) International Patent Classification⁷: C07C 229/46, 233/59, 323/32, C07D 213/38, 277/28, 277/34, 295/13, 307/52, 333/20, 407/12, A61K 31/196, 31/165, 31/341,
- 31/381, 31/426
- (21) International Application Number:

PCT/US2004/038126

(22) International Filing Date:

15 November 2004 (15.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/523,532

19 November 2003 (19.11.2003) US

- (71) Applicant (for all designated States except US): **SMITHKLINE BEECHAM** CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CORBETT, David, Francis [GB/GB]; GlaxoSmithKline, New Frontiers Science Park N & S, Third Avenue, Harlow Essex CM 19 5AW (GB). DWORNIK, Kate, Anna [US/US]; Glaxo-SmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). GARRIDO, Dulce, Maria Triangle Park, NC 27709 (US). GARRIDO, Dulce, Maria [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). MCKE-OWN, Stephen, Carl [GB/GB]; GlaxoSmithKline, New Frontiers Science Park N & S, Third Avenue, Harlow Essex CM 19 5AW (GB). MILLS, Wendy, Yoon [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). PEAT, Andrew, James [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box ning of each regular issue of the PCT Gazette. [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box

13398, Research Triangle Park, NC 27709 (US). SMAL-LEY, Terrence, Lee, Jr. [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

(57) Abstract: The present invention relates generally to novel therapeutic compounds and more particularly their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation. (57) Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds,